 Braxia Scientific Corp. CSE:BRAX, OTC:BRAXF has announced an increase in revenues for its second quarter and the first half ended September 30, 2022, with in-clinic treatment rising by 34.5 as it continues to build on its core strengths and priorities. The company also said it also evaluating strategic capital market opportunities to create shareholder value. 